JP2003517839A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003517839A5 JP2003517839A5 JP2001546906A JP2001546906A JP2003517839A5 JP 2003517839 A5 JP2003517839 A5 JP 2003517839A5 JP 2001546906 A JP2001546906 A JP 2001546906A JP 2001546906 A JP2001546906 A JP 2001546906A JP 2003517839 A5 JP2003517839 A5 JP 2003517839A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- hiv
- nucleic acid
- acid construct
- gag
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 description 25
- 108020004707 nucleic acids Proteins 0.000 description 15
- 102000039446 nucleic acids Human genes 0.000 description 15
- 150000007523 nucleic acids Chemical class 0.000 description 15
- 241000124008 Mammalia Species 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- 108700004029 pol Genes Proteins 0.000 description 8
- 101150088264 pol gene Proteins 0.000 description 8
- 229960005486 vaccine Drugs 0.000 description 6
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 108700004026 gag Genes Proteins 0.000 description 4
- 101150098622 gag gene Proteins 0.000 description 4
- 101710149951 Protein Tat Proteins 0.000 description 3
- 108020000999 Viral RNA Proteins 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 108700004025 env Genes Proteins 0.000 description 3
- 101150030339 env gene Proteins 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 101710091045 Envelope protein Proteins 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 102100034349 Integrase Human genes 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 108010089520 pol Gene Products Proteins 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 108700004027 tat Genes Proteins 0.000 description 1
- 101150098170 tat gene Proteins 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17303699P | 1999-12-23 | 1999-12-23 | |
| US60/173,036 | 1999-12-23 | ||
| PCT/US2000/034985 WO2001046408A2 (en) | 1999-12-23 | 2000-12-22 | Molecular clones with mutated hiv gag/pol, siv gag and siv env genes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003517839A JP2003517839A (ja) | 2003-06-03 |
| JP2003517839A5 true JP2003517839A5 (enExample) | 2008-02-28 |
| JP4627950B2 JP4627950B2 (ja) | 2011-02-09 |
Family
ID=22630264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001546906A Expired - Lifetime JP4627950B2 (ja) | 1999-12-23 | 2000-12-22 | 変異ＨＩＶｇａｇ／ｐｏｌ、ＳＩＶｇａｇおよびＳＩＶｅｎｖ遺伝子を持つ分子クローン |
Country Status (8)
| Country | Link |
|---|---|
| EP (2) | EP1246913B1 (enExample) |
| JP (1) | JP4627950B2 (enExample) |
| AT (1) | ATE438714T1 (enExample) |
| AU (1) | AU785133B2 (enExample) |
| CA (1) | CA2395269C (enExample) |
| DE (1) | DE60042702D1 (enExample) |
| ES (2) | ES2329648T3 (enExample) |
| WO (1) | WO2001046408A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1980617A1 (en) | 1998-12-31 | 2008-10-15 | Novartis Vaccines and Diagnostics, Inc. | Improved expression of HIV polypeptides and production of virus-like particles |
| WO2000039304A2 (en) | 1998-12-31 | 2000-07-06 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| US6656706B2 (en) * | 1999-12-23 | 2003-12-02 | The United States Of America As Represented By The Department Of Health And Human Services | Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes |
| AU2002320314A1 (en) | 2001-07-05 | 2003-01-21 | Chiron, Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| US20030170614A1 (en) | 2001-08-31 | 2003-09-11 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
| AU2003229666A1 (en) * | 2002-05-08 | 2003-11-11 | Pharmacia Italia Spa | A chimeric reverse transcriptase and methods for identifying telomerase inhibitors |
| TW200613554A (en) | 2004-06-17 | 2006-05-01 | Wyeth Corp | Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV |
| GB201501523D0 (en) * | 2015-01-30 | 2015-03-18 | Univ Plymouth | Differential immune response modulation |
| US11820999B2 (en) * | 2017-04-03 | 2023-11-21 | American Gene Technologies International Inc. | Compositions and methods for treating phenylketonuria |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6174666B1 (en) * | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
| EP1080201B1 (en) * | 1998-05-22 | 2008-01-23 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Novel post-transcriptional regulatory elements and uses thereof |
| EP1980617A1 (en) * | 1998-12-31 | 2008-10-15 | Novartis Vaccines and Diagnostics, Inc. | Improved expression of HIV polypeptides and production of virus-like particles |
| IL146090A0 (en) * | 1999-04-26 | 2002-07-25 | Leuven K U Res & Dev | A synthetic gene for expression of a retroviral protein with wild type activity in eukaryotic cells |
-
2000
- 2000-12-22 ES ES00989415T patent/ES2329648T3/es not_active Expired - Lifetime
- 2000-12-22 EP EP00989415A patent/EP1246913B1/en not_active Expired - Lifetime
- 2000-12-22 EP EP09010047.0A patent/EP2128256B1/en not_active Expired - Lifetime
- 2000-12-22 CA CA2395269A patent/CA2395269C/en not_active Expired - Lifetime
- 2000-12-22 AU AU25923/01A patent/AU785133B2/en not_active Expired
- 2000-12-22 WO PCT/US2000/034985 patent/WO2001046408A2/en not_active Ceased
- 2000-12-22 ES ES09010047T patent/ES2420842T3/es not_active Expired - Lifetime
- 2000-12-22 DE DE60042702T patent/DE60042702D1/de not_active Expired - Lifetime
- 2000-12-22 AT AT00989415T patent/ATE438714T1/de not_active IP Right Cessation
- 2000-12-22 JP JP2001546906A patent/JP4627950B2/ja not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sawyer et al. | Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated | |
| US7572906B2 (en) | Viral vectors and host cells and methods of making and using them | |
| US7811578B2 (en) | Soluble chimeric peptide inhibitors of HIV entry comprising an IZ trimeric coiled-coil peptide and HIV gp41 N-helix coiled-coil peptide | |
| CA2331599C (en) | Replication defective hiv vaccine | |
| LEE et al. | Role of the carboxy-terminal portion of the HIV-1 transmembrane protein in viral transmission and cytopathogenicity | |
| Montefiori et al. | Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques | |
| Costa et al. | Interactions between Nef and AIP1 proliferate multivesicular bodies and facilitate egress of HIV-1 | |
| JP2003517839A5 (enExample) | ||
| Chen et al. | Mutations in the leucine zipper-like heptad repeat sequence of human immunodeficiency virus type 1 gp41 dominantly interfere with wild-type virus infectivity | |
| JP3938935B2 (ja) | 粘膜免疫応答の誘導方法および組成物 | |
| Franchini et al. | Genetic analysis of a new subgroup of human and simian T-lymphotropic retroviruses: HTLV-IV, LAV-2, SBL-6669, and STLV-IIIAGM | |
| WO2001046408A2 (en) | Molecular clones with mutated hiv gag/pol, siv gag and siv env genes | |
| US5847096A (en) | DNA constructs encoding CD4 fusion proteins | |
| AU2004200663B2 (en) | Viral vectors and their use | |
| Goh et al. | Expression of the art gene protein of human T-lymphotropic virus type III (HTLV-III/LAV) in bacteria | |
| JP5180422B2 (ja) | Ｈｉｖ浸入のペプチドインヒビター | |
| Zhang et al. | Human immunodeficiency virus type 1 gag-specific mucosal immunity after oral immunization with papillomavirus pseudoviruses encoding gag | |
| WO1993005147A1 (en) | Defective interfering hiv particles with chimeric cd4-env | |
| Altaner et al. | Human cells oľ neural origin are permissive for bovine leukemia virus | |
| Mustafa et al. | HIV-1 Env glycoproteins from two series of primary isolates: replication phenotype and immunogenicity | |
| AU2001292944A1 (en) | Peptide inhibitors of HIV entry | |
| Wainberg et al. | Vaccine and antiviral strategies against infections caused by human immunodeficiency virus | |
| Wong-Staal | The AIDS virus. What we know and what we can do about it | |
| Mills | Prospects for vaccination against HIV infection | |
| Ferdinand et al. | Perspectives of HIV vaccine developments |